Solid Net Debt vs Common Stock Shares Outstanding Analysis
SLDB Stock | USD 5.69 0.09 1.56% |
Solid Biosciences financial indicator trend analysis is much more than just breaking down Solid Biosciences LLC prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Solid Biosciences LLC is a good investment. Please check the relationship between Solid Biosciences Net Debt and its Common Stock Shares Outstanding accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Net Debt vs Common Stock Shares Outstanding
Net Debt vs Common Stock Shares Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Solid Biosciences LLC Net Debt account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Solid Biosciences' Net Debt and Common Stock Shares Outstanding is -0.18. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Solid Biosciences LLC, assuming nothing else is changed. The correlation between historical values of Solid Biosciences' Net Debt and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Solid Biosciences LLC are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Net Debt i.e., Solid Biosciences' Net Debt and Common Stock Shares Outstanding go up and down completely randomly.
Correlation Coefficient | -0.18 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from Solid Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Solid Biosciences LLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. The current year's Issuance Of Capital Stock is expected to grow to about 79.7 M, whereas Selling General Administrative is forecasted to decline to about 20.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 3.0M | 2.4M | 2.6M | 2.3M | Net Interest Income | 64K | 2.6M | 7.0M | 7.4M |
Solid Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Solid Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Solid Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 103.5M | 171.2M | 232.4M | 260.3M | 164.9M | 152.1M | |
Other Current Liab | 52K | 6.4M | 8.1M | 14.1M | 7.8M | 7.4M | |
Total Current Liabilities | 18.3M | 24.5M | 23.6M | 22.5M | 14.5M | 18.1M | |
Total Stockholder Equity | 80.0M | 132.1M | 208.2M | 211.7M | 126.5M | 82.2M | |
Net Tangible Assets | 80.0M | 132.1M | 208.2M | 211.7M | 243.4M | 255.6M | |
Net Debt | (69.0M) | (149.6M) | (117.1M) | (126.8M) | (47.8M) | (50.1M) | |
Retained Earnings | (316.3M) | (404.6M) | (476.8M) | (562.7M) | (658.8M) | (625.8M) | |
Accounts Payable | 7.1M | 3.3M | 4.5M | 3.2M | 2.0M | 4.0M | |
Cash | 76.0M | 154.7M | 119.1M | 155.4M | 74.0M | 92.2M | |
Cash And Short Term Investments | 83.5M | 154.7M | 207.8M | 213.7M | 123.6M | 130.5M | |
Common Stock Total Equity | 48K | 87K | 112K | 20K | 18K | 17.1K | |
Common Stock Shares Outstanding | 2.7M | 3.5M | 7.1M | 8.5M | 19.9M | 20.9M | |
Short Term Investments | 7.5M | 0.0 | 88.6M | 58.3M | 49.6M | 38.4M | |
Liabilities And Stockholders Equity | 103.5M | 171.2M | 232.4M | 260.3M | 164.9M | 152.1M | |
Non Current Liabilities Total | 5.1M | 14.6M | 568K | 26.1M | 23.9M | 29.3M | |
Other Current Assets | 1.5M | 4.2M | 14.7M | 8.8M | 10.1M | 5.1M | |
Other Stockholder Equity | 396.3M | 536.6M | 684.9M | 774.5M | 785.2M | 411.0M | |
Total Liab | 23.4M | 39.1M | 24.2M | 48.6M | 38.5M | 42.5M | |
Total Current Assets | 86.3M | 158.9M | 222.6M | 219.6M | 129.7M | 135.9M | |
Accumulated Other Comprehensive Income | 1K | 0.0 | (45K) | (68K) | 15K | 15.8K | |
Common Stock | 48K | 87K | 112K | 20K | 18K | 17.1K | |
Property Plant And Equipment Net | 16.6M | 11.7M | 7.6M | 38.6M | 33.2M | 16.6M | |
Non Current Assets Total | 17.2M | 12.3M | 9.8M | 40.6M | 35.2M | 18.2M | |
Property Plant And Equipment Gross | 16.6M | 11.7M | 19.3M | 49.6M | 45.9M | 48.2M | |
Non Current Liabilities Other | 5.1M | 1.3M | 568K | 26.1M | 30.0M | 31.5M | |
Property Plant Equipment | 16.6M | 11.7M | 6.5M | 9.7M | 11.1M | 9.1M | |
Net Invested Capital | 80.0M | 132.1M | 208.2M | 211.7M | 126.5M | 129.6M | |
Net Working Capital | 68.0M | 134.4M | 199.0M | 197.1M | 115.2M | 139.8M | |
Short Long Term Debt Total | 7.1M | 5.2M | 2.1M | 28.5M | 26.3M | 27.6M | |
Capital Surpluse | 396.3M | 536.6M | 684.9M | 774.5M | 890.6M | 597.6M | |
Capital Lease Obligations | 7.1M | 5.2M | 2.1M | 28.5M | 26.3M | 27.6M | |
Capital Stock | 48K | 87K | 112K | 20K | 18K | 17.1K | |
Short Term Debt | 1.9M | 4.4M | 3.0M | 5.1M | 4.6M | 3.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Solid Biosciences LLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Solid Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Solid Biosciences Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Solid Biosciences Llc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Solid Biosciences LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Solid Biosciences. If investors know Solid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Solid Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Quarterly Revenue Growth (1.00) | Return On Assets (0.35) | Return On Equity (0.66) |
The market value of Solid Biosciences LLC is measured differently than its book value, which is the value of Solid that is recorded on the company's balance sheet. Investors also form their own opinion of Solid Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Solid Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Solid Biosciences' market value can be influenced by many factors that don't directly affect Solid Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Solid Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Solid Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Solid Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.